GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » 6-1 Month Momentum %

Azitra (Azitra) 6-1 Month Momentum % : -84.94% (As of May. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Azitra 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-04), Azitra's 6-1 Month Momentum % is -84.94%.

The industry rank for Azitra's 6-1 Month Momentum % or its related term are showing as below:

AZTR's 6-1 Month Momentum % is ranked worse than
97.63% of 1517 companies
in the Biotechnology industry
Industry Median: 0.14 vs AZTR: -84.94

Competitive Comparison of Azitra's 6-1 Month Momentum %

For the Biotechnology subindustry, Azitra's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Azitra's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Azitra's 6-1 Month Momentum % falls into.


Azitra  (AMEX:AZTR) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Azitra  (AMEX:AZTR) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Azitra 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Azitra's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Azitra (Azitra) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » 6-1 Month Momentum %
Comparable Companies
CNTX NTRB KALA MYMD LSTA ICU MBIO AXLA EQ COCP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Website
https://www.azitrainc.com
Anitra Inc is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary director 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Norm Staskey officer: Chief Financial Officer 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Bios Azitra Co-invest I, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp 10 percent owner 100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc 10 percent owner
Francisco D. Salva director, officer: President and CEO 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill director, officer: Chief Operating Officer C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107